Mechanisms of action of drugs that prevent experimental diabetic retinopathy

Schepens Eye Research Institute, Boston MA

Investigators

Linked publications, trials & patents

Abstract

Abstract The ultimate goal of our work is to develop drug strategies for the prevention of diabetic retinopathy. Prevention has been brought within reach by the progressively wider implementation of intensive glycemic control, and we anticipate that the addition of drugs that are effective in pre-emptying the tissue effects of residual hyperglycemia and are safe for long-term administration will make prevention a reality. There are no adjunct drugs usable clinically, and there are no rigorous positive or negative information on the type of drugs that may be effective in the prevention of human diabetic retinopathy. We thus sought to learn from drugs that prevent experimental diabetic retinopathy which molecular processes must be silenced in the retinal vessels in order to prevent the sight-threatening damage induced by diabetes. We tested two drugs with different mechanisms of action (an aldose reductase inhibitor and aspirin at low-intermediate concentrations) reasoning that molecular targets common to the two drugs would identify candidate pathogenic pathways to be investigated further. The experiments showed that, in rats, (i) diabetes changes the expression of multiple genes in retinal vessels, (ii) the TGF-[unreadable] pathway was the single functional pathway mostly affected by diabetes, and (iii) the two drugs had private as well as common targets, with the TGF-[unreadable] pathway being one of the two common functional targets. Given that overactivity of the TGF-[unreadable] pathway could explain much of the vascular histopathology of diabetic retinopathy, and based on additional results documenting increased TGF-[unreadable] signaling in diabetic retinal vessels, we plan to test the hypothesis that excess TGF-[unreadable] signaling contributes to the characteristic vascular pathology of diabetic retinopathy. The project is made especially exciting by the opportunity to use a new small molecule inhibitor of TGF-[unreadable] type I receptor kinase, named SM16, that is orally active, a most appealing feature for translational steps. We aim to develop and validate in diabetic rats a drug strategy based on SM16 for non-invasive, long-term, and on-target prevention of the excess TGF-[unreadable] signaling in retinal vessels. The precise aim is to bring TGF-[unreadable] signaling back to control values without reducing basal TGF- [unreadable] activity. We will use the inhibitor to learn the molecular effects of excess TGF-[unreadable] signaling on diabetic retinal vessels. We will then test whether by taking away such effects, the retinal capillaries are protected from the cell death and remodeling that lead to their final demise in diabetes. In the same rats we will also examine the effects of SM16 on the development of the typical renal pathology. Finally, we will examine the TGF-[unreadable] pathway in human diabetic retinal vessels (postmortem eyes). A combination of positive results in the preclinical studies and the human diabetic retina will identify excess TGF-[unreadable] signaling as a contributor to the vascular pathology of diabetic retinopathy and will stimulate investigation and development of drugs to modulate safely TGF-[unreadable] activity in humans. In addition, the studies are poised to generate a paradigm for applications of anti-TGF-[unreadable] therapy to other pathologies.